CDC to offer more Ebola training to healthcare industry

Laura Pedulli | | Health Exec | Policy & Regulations

In response to news that a nurse has contracted Ebola, a spokesperson from the Centers or Disease Control and Prevention (CDC) announced that the agency would issue more specific instructions and explanations on the use of protective gear, reports The New York Times.

“Every U.S. healthcare facility needs to have the capability to initially handle a case. Even if the patient is going to be transferred to another facility, they need to be able to handle the first moments,” said CDC spokeswoman Abbigail Tumpey, according to the article.

Read more below:

C.D.C. Will Offer More Ebola Training to Health Care Workers

Laura Pedulli

Related Content

Q&A: Proposed changes to Social Security Act would recognize pharmacists as healthcare providers
10 signs AI is ‘eating the world (of venture capital)’
Mangione now faces federal charges, death penalty in murder of UHC CEO
FDA issues Class I recall on counterfeit infusion pump batteries
FDA issues alert on PCNL sheath safety after patient death
DOJ sues CVS over unlawful opioid prescriptions and reimbursement

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.